Skip to content
MARKETS / NASDAQ / SOPH
NASDAQ · SERVICES-COMPUTER PROCESSING & DATA PREPARATION · MID CAP

SOPHiA Genetics SA SOPH

7 fiscal years on record · USD · FY2025 reported · SEC filings only
$77.3M
▲ 18.6% YoY
$-79.0M
$-36.5M
In brief

What this company does

In July 2021, the company completed its initial public offering on the Nasdaq Global Select Market and its ordinary shares are listed under the ticker symbol "SOPH". Its platform, SOPHiA DDM, standardizes, computes and analyzes digital health data and is used across decentralized locations to break down data silos. It offers a broad range of applications used by healthcare providers, clinical and life sciences research laboratories and biopharmaceutical companies for precision medicine across oncology, rare diseases, infectious diseases, cardiology, neurology, metabolism and other disease areas. As of December 31, 2025, the company served more than 993 hospital, laboratory and biopharma customers globally through its SOPHiA DDM Platform and related solutions, applications, products, and services, and its platform has supported the analysis of approximately 2,300,000 genomic profiles.

Written from the business description in SOPHiA GENETICS SA's annual report to the U.S. Securities and Exchange Commission, filed 3 March 2026. Every sentence was checked against that document before publication.

Growth
USD 77.3M
Revenue, FY2025 · full 7-year series below
Revenue $M Net income $M
FY2025 · Revenue 77.3 · Net income -79.0
40M-40M-80M2019202020212022202320242025
Compound annual growth
+17.6%
+22.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +22.2% a year over five years.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability
−102 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -91.8% · Net -102.2%
-50%-100%-150%2019202020212022202320242025
ROE

Not available in our data for this period.

Cash & shareholders
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -36.5
-25.0M-50.0M2019202020212022202320242025

Total assetsUSD 163.0M
CashUSD 70.3M
Current ratio1.96×

Not available: we don't have the total debt figure for this period.

The 7-year record
7 fiscal years
Every figure from documents filed with the SEC · USD
row low → row highnegative
Metric 2025202420232022202120202019
Revenue $B0.10.10.10.00.00.00.0
Operating income $B−0.1−0.1−0.1−0.1−0.1−0.0·
EBITDA $B·······
Income tax $B0.00.00.0−0.00.0−0.00.0
Net income $B−0.1−0.1−0.1−0.1−0.1−0.0−0.0
Free cash flow $B−0.0−0.0−0.1−0.1−0.1−0.0−0.0
EPS, diluted $−1.17−0.95−1.22−1.36−1.33−0.93·
Dividend / sh $·······
Payout %·······
ROE %·······

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

Provenance
Company facts, as filed
How we verify · 0 failures in 32 reconciliationsAUDITED

Reconciled in 7 of 19 fiscal years. 63 checks could not be computed.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquiditymoeda_consistente0 failures
ActivityServices-Computer Processing & Data Preparation
Listed onNASDAQ
Incorporated inoutside the United States — SEC code V8
Fiscal year endsDecember 31
SEC categoryemerging growth company
Data on record since2019

Share this section

Download image